ClinVar Miner

Submissions for variant NM_000020.3(ACVRL1):c.917C>T (p.Ala306Val)

gnomAD frequency: 0.00013  dbSNP: rs150038846
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV001000664 SCV001157692 uncertain significance Telangiectasia, hereditary hemorrhagic, type 2 2019-03-24 criteria provided, single submitter clinical testing The ACVRL1 c.917C>T; p.Ala306Val variant (rs150038846), to our knowledge, is not reported in the medical literature or gene-specific databases. This variant is found in the general population with an overall allele frequency of 0.01% (25/282490 alleles) in the Genome Aggregation Database. Other amino acid substitutions at this codon (p.Ala306Glu, p.Ala306Pro) have been reported in individuals with hereditary haemorrhagic telangiectasia (HHT) (Lesca 2004, Torring 2014), and p.Ala306Pro exhibits altered localization and defective activity (Alaa El Din 2015), although it is uncertain if both other variants at this position are disease-causing. The alanine at codon 306 is moderately conserved, but computational analyses (SIFT, PolyPhen-2) predict that the p.Ala306Val variant is tolerated. Although the allele frequency of ACVRL1 p.Ala306Val is high for the known prevalence of HHT, due to limited clinical information and the reports of other amino acid substitutions at the same residue, the clinical significance of this variant is uncertain at this time. References: Alaa El Din F et al. Functional and splicing defect analysis of 23 ACVRL1 mutations in a cohort of patients affected by Hereditary Hemorrhagic Telangiectasia. PLoS One. 2015 Jul 15;10(7):e0132111. Lesca G et al. Molecular screening of ALK1/ACVRL1 and ENG genes in hereditary hemorrhagic telangiectasia in France. Hum Mutat. 2004 Apr;23(4):289-99. Torring PM et al. National mutation study among Danish patients with hereditary haemorrhagic telangiectasia. Clin Genet. 2014 Aug;86(2):123-33.
Illumina Laboratory Services, Illumina RCV001000664 SCV001270872 uncertain significance Telangiectasia, hereditary hemorrhagic, type 2 2017-04-27 criteria provided, single submitter clinical testing This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance.
Invitae RCV001000664 SCV001485952 uncertain significance Telangiectasia, hereditary hemorrhagic, type 2 2022-03-02 criteria provided, single submitter clinical testing This sequence change replaces alanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 306 of the ACVRL1 protein (p.Ala306Val). This variant is present in population databases (rs150038846, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with ACVRL1-related conditions. ClinVar contains an entry for this variant (Variation ID: 811065). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
GeneDx RCV002249610 SCV002520112 uncertain significance not provided 2022-05-20 criteria provided, single submitter clinical testing In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge
Ambry Genetics RCV002445157 SCV002683265 benign Cardiovascular phenotype 2023-05-02 criteria provided, single submitter clinical testing This alteration is classified as benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.
Fulgent Genetics, Fulgent Genetics RCV001000664 SCV002817029 uncertain significance Telangiectasia, hereditary hemorrhagic, type 2 2022-04-19 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.